secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001937653-23-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks Q1 net loss down 66% to $24.4M; revenue surges to $35.6M on Jazz deal; cash runway through 2026
--------------------------------------------------------------------------------

- Net loss $24.4M vs $72.6M in Q1 2022 (-66%); revenue $35.6M vs $1.9M, driven by Jazz collaboration.
- Cash & securities $412.4M; reaffirms 2023 net operating cash burn guidance $90-120M and cash runway through at least 2026.
- R&D expense decreased $16.6M to lower levels; Non-GAAP R&D down $14.7M.
- Will present pivotal Phase 2b zanidatamab data at ASCO (oral presentation); ZW191/ZW171 on track for IND filings in 2024.
- Board strengthened with appointment of Derek Miller, adding business development and commercial expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765323000020/0001937653-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765323000020/zyme-20230508.htm
  HTML page:      https://secwatch.observer/filing/0001937653-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer